Natera
NTRA
$228.80
-1.13%
Natera, Inc. is a diagnostic and research company operating in the healthcare sector, specifically within medical diagnostics and research. The company leverages proprietary molecular and bioinformatics technology to develop and commercialize key products, including its Panorama non-invasive prenatal test (NIPT), Horizon carrier screening (HCS), Signatera molecular residual disease (MRD) test for cancer monitoring, and Prospera for assessing organ transplant rejection. Natera has established itself as a disruptive leader in the cell-free DNA testing market, particularly in oncology and women's health, by offering differentiated, high-complexity tests. The current investor narrative is intensely focused on the company's path to sustainable profitability, driven by the rapid adoption and reimbursement expansion of its Signatera oncology test, while debates center on the sustainability of its recent quarterly net income against a backdrop of historical losses and the competitive pressures in the NIPT space.…
NTRA
Natera
$228.80
Related headlines
Investment Opinion: Should I buy NTRA Today?
Rating & Thesis: Hold. Natera is a compelling growth story at an inflection point, but its premium valuation demands flawless execution, making the risk/reward balanced at current levels. The bullish analyst consensus underscores the potential, but the price already reflects much of the optimism.
Supporting Evidence: The Hold rating is supported by four key data points: 1) Robust revenue growth of 39.8% YoY, 2) A positive profitability inflection with Q4 net income of $47.3M, 3) A premium but not extreme valuation at 13.6x trailing sales (EV/Sales 12.3x), and 4) Strong financial health indicated by positive TTM FCF of $96.6M and minimal debt (D/E 0.125). The stock's 18% pullback from its 52-week high provides a slightly better entry point than recent peaks.
Risks & Conditions: The two biggest risks are growth deceleration and multiple compression. This Hold would upgrade to a Buy if the PS ratio compresses below 10x on sustained profitability, or if revenue growth re-accelerates above 40% for consecutive quarters. It would downgrade to Sell if quarterly revenue growth decelerates below 25% or if the company returns to consistent quarterly losses. Relative to its own growth trajectory and the analyst community's bullish outlook, the stock is fairly valued to slightly overvalued, leaving little margin for error.
Sign up to view all
NTRA 12-Month Price Forecast
The outlook is balanced with a 55% probability assigned to the base case of continued strong growth and volatile but improving profits. The bull case is credible given the powerful Q4 inflection and analyst conviction, but the premium valuation caps near-term upside without flawless execution. The bear case, while lower probability, carries significant downside risk to the 52-week low of $131.81 if growth stumbles. The stance would upgrade to bullish on confirmation of sustained quarterly profitability and maintenance of >35% revenue growth. It would turn bearish on a return to consistent losses or growth deceleration below 25%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $297.44 and implied upside of +30.0% versus the current price.
Average Target
$297.44
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$183 - $297
Analyst target range
Analyst coverage for Natera appears limited with data indicating only 7 analysts providing estimates, though the institutional ratings list shows activity from over a dozen major firms, suggesting stronger coverage than the estimate count implies. The consensus sentiment is decidedly bullish, as evidenced by recent institutional actions including reiterated 'Overweight' from Morgan Stanley, 'Outperform' from Baird and Evercore ISI, and 'Buy' from Guggenheim and Canaccord Genuity. The average revenue estimate for the period is $5.54 billion, with a range from $5.37 billion to $5.68 billion, indicating high conviction in continued top-line growth. A specific consensus price target is not provided in the dataset, but the pattern of ratings implies significant upside is expected by the analyst community. The target range, while not explicitly stated in price terms, can be inferred from the wide dispersion in revenue estimates, signaling some uncertainty around the exact growth trajectory but overall strong confidence. The recent news of a prominent billionaire investor taking a large position adds a layer of institutional validation to the bullish thesis. The sustained series of 'Outperform' and 'Buy' reiterations throughout late 2025 and early 2026, without downgrades, indicates strengthening analyst conviction in the company's fundamental turnaround and long-term growth story in oncology diagnostics.
Bulls vs Bears: NTRA Investment Factors
The evidence currently tilts bullish, driven by the powerful combination of accelerating revenue growth (39.8% YoY) and a clear inflection to quarterly profitability ($47.3M net income). The bear case is anchored in valuation, with the stock's premium sales multiple (13.6x PS) pricing in near-perfect execution. The single most important tension in the investment debate is whether Natera's Signatera-driven growth can sustain its current pace long enough to grow into its valuation and deliver consistent annual profits, thereby justifying its premium multiple. If growth decelerates before profitability solidifies, the stock is highly vulnerable to a sharp derating.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 39.8% YoY to $665.5 million, demonstrating accelerating demand for Natera's core tests. This robust top-line expansion is the primary driver of the investment thesis, indicating strong market adoption.
- Profitability Inflection Achieved: The company delivered a positive net income of $47.3 million in Q4 2025, a sharp reversal from a $87.5 million loss in Q3. This inflection to a 7.1% net margin suggests the business model is scaling towards sustainable profitability.
- Strong Cash Generation: Natera generated $96.6 million in TTM free cash flow and $37.8 million in Q4, proving its ability to fund growth internally. This is supported by a healthy gross margin of 67.1% and a robust current ratio of 3.39.
- Bullish Analyst Conviction: Multiple major institutions (Morgan Stanley, Baird, Evercore ISI) have reiterated 'Overweight' or 'Buy' ratings in recent months. This consensus reflects strong conviction in the company's oncology growth story and path to profitability.
Bearish
- Extreme Earnings Volatility: Despite the positive Q4, TTM EPS remains negative at -$0.0066, and the forward P/E is a nonsensical -1110.5x. This highlights that consistent, annual profitability is not yet established, creating valuation uncertainty.
- Premium Valuation on Sales: The stock trades at a trailing PS ratio of 13.6x and EV/Sales of 12.3x, a significant premium typical of hyper-growth expectations. Any deceleration in the 39.8% revenue growth rate could trigger severe multiple compression.
- High Market Volatility: With a beta of 1.54, NTRA is 54% more volatile than the S&P 500. This was evidenced by a recent -28.2% max drawdown, indicating the stock is prone to sharp, sentiment-driven sell-offs despite strong fundamentals.
- Competitive NIPT Market Pressures: While Signatera in oncology is a key growth driver, the core Panorama NIPT business operates in a competitive, reimbursement-sensitive market. Sustaining high growth requires continuous market share gains and reimbursement wins.
NTRA Technical Analysis
The prevailing price trend for Natera is one of significant volatility within a broad consolidation range, following a strong longer-term uptrend. The stock has gained 35.34% over the past year, yet it is currently trading at approximately 90% of its 52-week high of $256.36, having pulled back from that peak. This positioning near the upper end of the 52-week range suggests the stock retains substantial momentum but may be susceptible to profit-taking, especially given the -0.24% decline over the past six months indicates a recent period of churn. Recent short-term momentum is notably bullish and diverging from the flattish six-month trend, with the stock up 18.04% over the past month and 18.50% over the past three months. This acceleration suggests renewed buying interest, potentially driven by fundamental catalysts, as the 1-month relative strength of 17.30 points significantly outperforms the broader market. Key technical levels are clearly defined by the 52-week high of $256.36 as major resistance and the 52-week low of $131.81 as critical support. A decisive breakout above $256.36 would signal a resumption of the primary uptrend, while a breakdown below $131.81 would indicate a more severe bearish reversal. The stock's beta of 1.54 confirms it is approximately 54% more volatile than the S&P 500, which necessitates larger position sizing allowances for institutional investors and implies higher risk-adjusted return expectations.
Beta
1.54
1.54x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$132-$256
Price range past year
Annual Return
+33.1%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | -0.2% |
| 3m | +17.6% | +14.0% |
| 6m | -2.9% | +7.8% |
| 1y | +33.1% | +25.3% |
| ytd | -0.0% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory exhibits robust and accelerating growth, a core pillar of the investment thesis. For Q4 2025, the company reported revenue of $665.5 million, representing a substantial 39.79% year-over-year increase. This growth is primarily driven by its core Product segment, which contributed $661.16 million in the latest period, indicating the vast majority of sales are from test volumes rather than licensing. The multi-quarter trend shows consistent sequential revenue increases from $501.83 million in Q1 2025 to the Q4 level, underscoring strong commercial execution. Profitability remains a mixed but improving picture; the company achieved a rare net income of $47.26 million in Q4 2025, with a net margin of 7.10%, marking a significant inflection from losses in prior quarters like Q3 2025's net loss of $87.54 million. Gross margins are healthy and stable, reported at 67.14% for Q4, indicating strong pricing power and operational efficiency in its testing business. The balance sheet and cash flow position is solid, providing a runway for continued growth investments. The company boasts a strong current ratio of 3.39 and a very low debt-to-equity ratio of 0.125, indicating minimal financial leverage risk. Importantly, Natera generated positive free cash flow of $96.61 million on a trailing twelve-month basis and $37.82 million in the latest quarter, demonstrating an emerging ability to fund operations internally despite significant capital expenditures, which were $36.07 million in Q4 for property, plant, and equipment.
Quarterly Revenue
$665500000.0B
2025-12
Revenue YoY Growth
+0.39%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$96613000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given Natera's net income was positive in the latest quarter but the trailing twelve-month EPS remains negative at -$0.0066, we lead with the Price-to-Sales (PS) ratio as the primary valuation metric, as profitability is not yet consistent on an annual basis. The stock trades at a trailing PS ratio of 13.58x and an Enterprise Value-to-Sales (EV/Sales) of 12.27x. The forward-looking valuation gap is stark, with a forward PE ratio of -1110.52, reflecting analyst expectations for significant earnings growth but also the mathematical distortion of a low positive EPS estimate against a high stock price. Compared to industry averages, specific data is not available in the provided dataset, but a PS ratio near 13.6x is typically at a premium for a diagnostics company, justified only by hyper-growth expectations and potential for margin expansion, which Natera's 39.8% YoY revenue growth may support. Historically, Natera's valuation has compressed significantly from pandemic-era highs but has recently re-rated. The current PS ratio of 13.58x sits well below its historical peak observed in Q1 2021 of 57.79x but is above levels seen in late 2022 and 2023 (e.g., 18.20x in Q4 2022). This positioning suggests the market is pricing in improved fundamentals and growth sustainability compared to the past two years, but not the speculative frenzy of 2021, indicating a more mature, growth-focused valuation.
PE
-150.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -124x~166x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is earnings volatility, as evidenced by the swing from a $87.5M Q3 loss to a $47.3M Q4 profit. While TTM free cash flow is positive at $96.6M, the operating margin remains negative at -13.4%, indicating core operations are still not consistently profitable without potential one-time benefits. Revenue concentration risk is moderate but evolving; growth is heavily reliant on the success and reimbursement expansion of the Signatera oncology test, though the legacy NIPT business provides a revenue base.
Market & Competitive Risks: Valuation compression is the paramount market risk. Trading at a PS ratio of 13.6x, well above historical lows, the stock is priced for hyper-growth. A slowdown in the 39.8% YoY revenue growth rate, increased competition in MRD testing, or adverse reimbursement decisions could trigger a significant multiple contraction. The stock's high beta of 1.54 also makes it highly sensitive to broader market sell-offs, particularly those affecting growth stocks.
Worst-Case Scenario: The worst-case scenario involves a 'growth scare' where Signatera adoption plateaus or faces new competitive entrants sooner than expected, coupled with a broader market downturn compressing growth stock multiples. This could lead to a simultaneous earnings miss and derating. A realistic downside could see the stock re-testing its 52-week low of $131.81, representing a potential loss of approximately -43% from the recent price of ~$231. Such a move would align with the stock's demonstrated -28.2% max drawdown during recent volatility.
FAQ
The key risks are, in order of severity: 1) Valuation Compression: The premium PS ratio of 13.6x is vulnerable if 39.8% revenue growth decelerates. 2) Profitability Volatility: The swing from a $87.5M Q3 loss to a $47.3M Q4 profit shows earnings are not yet stable. 3) Competitive & Reimbursement: The oncology MRD market is attractive and will draw competition, and growth depends on favorable insurance coverage decisions. 4) Market Sensitivity: With a beta of 1.54, NTRA will fall more than the market in a downturn, as seen in its -28.2% max drawdown.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $210 and $256, assuming growth moderates but remains strong (~33-35%) with choppy profitability. The Bull Case (30% probability) targets $256 to $300, driven by accelerated Signatera adoption and sustained quarterly profits. The Bear Case (15% probability) warns of a drop to $132-$190 if growth stalls and losses return. The most likely outcome is the Base Case, hinging on the assumption that the company can maintain its current growth momentum without major setbacks.
NTRA is fairly valued to slightly overvalued based on current metrics. The primary valuation metric is the Price-to-Sales ratio of 13.6x (EV/Sales 12.3x), which is a premium multiple justified only by its hyper-growth rate of 39.8% YoY. Compared to its own history, the multiple is well below pandemic-era peaks (~58x) but above levels from 2022-2023. The market is paying a premium price that implies expectations for sustained high growth and rapid margin expansion. If growth decelerates, the stock is unequivocally overvalued; if growth persists and profits materialize consistently, it could be fairly valued.
NTRA is a good buy for aggressive growth investors comfortable with high volatility, but it carries significant risk. The stock offers exposure to a company with 39.8% revenue growth and a recent inflection to profitability, supported by bullish analyst sentiment. However, at a PS ratio of 13.6x, it is priced for near-perfect execution. The potential 43% downside to its 52-week low underscores the risk. It is a good buy for those who believe Signatera adoption will continue to accelerate and who can tolerate sharp price swings, but it is not a core, low-risk holding.
NTRA is primarily suitable for a long-term investment horizon of 3-5 years. The investment thesis is based on the multi-year adoption curve of its Signatera test and the journey to consistent profitability, which are not short-term stories. The stock's high beta of 1.54 and lack of a dividend make it a poor candidate for short-term trading or income. Investors should be prepared to hold through significant volatility to capture the potential growth. A minimum holding period of 18-24 months is suggested to allow for the execution of the growth plan and for quarterly earnings volatility to smooth out.